Mario Romero Cristóbal

40 - DEVELOPMENT OF LIVER ATROPHY RESHAPES THE TRANSCRIPTOMIC PROFILES OF EXTRAHEPATIC ORGANS IN EXPERIMENTAL CIRRHOSIS

Javier Vaquero, Iris Asensio, Marta Puerto, Elena Vázquez-Ogando et autres

Radiological-pathological Concordance in Tumor Staging of HCC Patients Undergoing Liver Transplantation: Associated Factors and Impact on Post-transplant Outcomes

Adnan Alsourani, M.M. Salcedo Plaza, Mario Romero Cristóbal, José Ángel López Baena

es (code pays fourni par la source)

TOP-002 Validation of the gender-equity model for liver allocation (GEMA) in a nationwide cohort of liver transplant candidates in Spain

Manuel Rodríguez‐Perálvarez, Gloria de la Rosa, Antonio M. Gómez-Orellana, Victoria Aguilera Sancho et autres

First consensus document of waiting list prioritization for liver transplantation by the Spanish Society of Liver Transplantation (SETH)

Itxarone Bilbao, Laura Lladó, Alba Cachero, Isabel Campos‐Varela et autres

Spain is worldwide leader in deceased donation rates per million habitants and count on a strong network of twenty-five liver transplant institutions. Although the access to liver transplantation is higher than in other countries, approximately 10% of patients qualifying for liver transplantation …

es (code pays fourni par la source)

Implementation and impact of an antibiotic control program and multidrug-resistant bacterial colonization in a liver transplant unit

Ainhoa Fernández, Clara Díez-Picazo, Carmen Iglesias Sobrino, Celia Trueba Collado et autres

INTRODUCTION: infections by multidrug-resistant bacteria are a major cause of morbidity and mortality in transplant patients. OBJECTIVE: a retrospective single-center study was performed to evaluate the implementation of an Antimicrobial Treatment Optimization Program (PROA) on multidrug-resistant bacteria colonization and infection after liver …

es (code pays fourni par la source)

Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study

Massimo Alberto Iavarone, Federica Invernizzi, Tommy Ivanics, Stefano Mazza et autres

Safety of regorafenib in hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT) has been recently demonstrated. We aimed to assess the survival benefit of regorafenib compared with best supportive care (BSC) in LT patients after sorafenib discontinuation. This observational multicenter retrospective study …

it, ca, es, de, at, fr, ar, dk, nz (code pays fourni par la source)

Regorafenib improves survival after sorafenib in patients with recurrent HCC after liver transplantation

Massimo Alberto Iavarone, Federica Invernizzi, Tommy Ivanics, Stefano Mazza et autres

it, ca, es, de, at, fr, ar, dk (code pays fourni par la source)

Changes in humoral immune response after SARS-CoV-2 infection in liver transplant recipients compared to immunocompetent patients

A. Marcos, Margarita Salcedo, Rafael Alonso, ML Rodríguez Perálvarez et autres

Risk assessment of clinically significant portal hypertension by means of hepatosplenic volumetry in compensated cirrhosis

Mario Romero Cristóbal, Ana Paula Grotti Clemente, Enrique Ramón Botella, Olga Delgado Ortega et autres

Profilaxis y tratamiento de la infección por virus de la hepatitis B en el trasplante hepático. VII Documento de consenso de la Sociedad Española de Trasplante Hepático

Inmaculada Fernández, Juan Manuel Pascasio, Jordi Colmenero, Carolina Almohalla et autres

es (code pays fourni par la source)

Long-term outcomes and clinical impact of anti-HLA donor-specific antibodies (DSA) after liver transplantation: prospective study in a pilot cohort.

Raquel Díaz Ruiz, Mario Romero Cristóbal, Ainhoa Fernández Yunquera, Fernando Díaz‐Fontenla et autres

INTRODUCTION: the presence of donor-specific antibodies (DSA) is thought to affect survival of the allograft and patient after liver transplantation (LT). However, their significance is not well understood. PATIENTS AND METHODS: a prospective study was performed of 32 adult patients who underwent …

es (code pays fourni par la source)

Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation

Massimo Alberto Iavarone, Federica Invernizzi, Carolin Czauderna, Marco Sanduzzi‐Zamparelli et autres

Regorafenib is one option for second-line treatment of hepatocellular carcinoma (HCC), improving overall survival (OS) of sorafenib-tolerant patients who develop progression. We aim to evaluate the safety and outcomes of regorafenib as second-line treatment for HCC recurrence after liver transplantation (LT). This …

it, de, es, fr, ar, at, dk (code pays fourni par la source)